Doripenem is a carbapenem antibiotic that is indicated for the treatment of complicated intra-abdominal infection and complicated urinary tract infection [1] . In a general sense, doripenem is similar to other antipseudomonal carbapenems, in that it demonstrates in vitro activity against a wide range of gram-negative and gram-positive pathogens [1] [2] [3] . Certain features of doripenem, however, such as its potent activity against Pseudomonas aeruginosa [4, 5] and its limited ability to promote the emergence of carbapenem-resistant mutants in vitro [6, 7] , may distinguish this agent from its counterparts in the carbapenem class [8] . This review critically addresses the in vitro activity profile of doripenem, the characteristics of which may make the drug a uniquely valuable therapeutic option among the carbapenem antibiotic agents.
teria [1] [2] [3] . Like other carbapenems, doripenem is considered to be active against most isolates of gram-positive and gram-negative pathogens (including aerobes and anaerobes), with the exception of Stenotrophomonas maltophilia, Burkholderia cepacia, methicillin-resistant Staphylococcus aureus, and Enterococcus faecium. A more detailed examination of the available data demonstrates that doripenem provides a broad spectrum of antimicrobial coverage and also comparatively potent activity against gram-negative organisms that have an increased potential for the development of drug resistance, such as P. aeruginosa, Acinetobacter species, and members of the Enterobacteriaceae family. The in vitro activity of doripenem against clinically relevant grampositive and gram-negative pathogens has been assessed in a number of published studies, including 2 that have allowed direct comparison of the in vitro activity profile of doripenem with those of both imipenem and meropenem. In 1 of those 2 studies, Brown and Traczewski [5] tested the in vitro activity of doripenem, imipenem, and meropenem against 2137 recently collected bacterial isolates that were representative of the pathogen types detected in potential indications for doripenem. In the other study, Tsuji et al. [9] tested the in vitro activity of the same 3 agents, along with 3 other blactams, against a collection of 978 pathogenic isolates, most of which were collected at a single Japanese hospital. The susceptibility data obtained from these NOTE. Assessment was done in 2 separate studies, which included (1) a US-based study in which doripenem, imipenem, and meropenem were tested in vitro against 2137 recently collected bacterial isolates and (2) a Japanese study in which doripenem, imipenem, and meropenem, along with 3 other b-lactams, were tested in vitro against a collection of 886 pathogenic isolates. MIC 50 , minimum inhibitory concentration at which 50% of all isolates tested were susceptible to the agent of interest. MIC 90, minimum inhibitory concentration at which 90% of all isolates tested were susceptible to the agent of interest. Data are from Lister [2] . studies showed that, for most gram-negative species, the minimum inhibitory concentrations of doripenem at which 50% and 90% of all isolates of these species are susceptible (MIC 50 and MIC 90 , respectively) are similar to those of meropenem and lower than those of imipenem. For most gram-positive species, the MIC 50 and MIC 90 of doripenem are similar to those of imipenem and lower than those of meropenem (table 1) [2, 5, 9] . Furthermore, with regard to gram-positive pathogens, the same studies found that doripenem, meropenem, and imipenem had identical MIC 50 values with respect to Streptococcus pneumoniae and that the MIC 50 of doripenem with respect to S. aureus and E. faecalis was 2-fold higher than the corresponding MIC 50 of imipenem. The MIC 50 of meropenem with respect to S. aureus and E. faecalis was 4 times higher than the corresponding MIC 50 of imipenem [2, 5, 9] . With regard to gramnegative pathogens, these studies found that the MIC 50 of doripenem with respect to P. aeruginosa was the same as the corresponding MIC 50 of meropenem and 4 times lower than the corresponding MIC 50 of imipenem. In addition, among several different members of the Enterobacteriaceae family, the MIC 50 and MIC 90 of doripenem and meropenem were similar and were substantially lower than the corresponding MIC 50 and MIC 90 of imipenem. These findings are mirrored by others that cumulatively demonstrate how the intrinsic activity of doripenem compares with that of other carbapenems and that the drug is more potent in vitro against some clinically important pathogens. Of note, when compared outside the carbapenem class with either ceftazidime or cefpirome, doripenem and, in most cases, imipenem and meropenem had lower MIC 50 and MIC 90 values with respect to staphylococci, streptococci, P. aeruginosa, and several species of Enterobacteriaceae [9] .
The Tracking Resistance in the US Today (TRUST)-11 surveillance study monitored the antimicrobial susceptibility of isolates collected from clinical laboratories throughout the United States from January through July 2007 (8574 total isolates: 4866 Enterobacteriaceae, 866 P. aeruginosa, 257 Acinetobacter species, 175 S. maltophilia, 2187 Staphylococcus species, and 223 E. faecalis isolates) by testing them at a central facility (Eurofins Medinet; Herndon, VA) with use of the broth microdilution method. The study determined that the MIC 90 of doripenem with respect to P. aeruginosa was lower than the corresponding MIC 90 values of the other carbapenems evaluated (doripenem, 4 mg/mL; imipenem, 16 mg/mL; and meropenem, 8 mg/mL) (Ortho-McNeil-Janssen Pharmaceuticals, unpublished data). Among the P. aeruginosa isolates tested in this surveillance study, 32% of the 151 isolates nonsusceptible to imipenem, as well as 8.5% of the 94 isolates nonsusceptible to meropenem, remained susceptible to doripenem (MIC р2 mg/ mL). An analysis of susceptibility data from the same study also demonstrated that the activity of doripenem against Enterobacteriaceae, such as Escherichia coli (MIC 90 of doripenem, 0.03 mg/mL; MIC 90 of meropenem, 0.03 mg/mL; MIC 90 of imipenem, 0.25 mg/mL), Klebsiella pneumoniae (0.06 mg/mL, 0.03 mg/mL, and 0.5 mg/mL, respectively), and Proteus mirabilis (0.25 mg/mL, 0.12 mg/mL, and 2.0 mg/mL, respectively), was generally comparable to that of meropenem and was ∼10 times more potent than that of imipenem. In addition, the TRUST-11 study showed that the activity of doripenem against Acinetobacter baumannii was comparable to that of imipenem and meropenem (MIC 90 of doripenem, 132 mg/mL; MIC 90 of imipenem, 132 mg/mL; MIC 90 of meropenem, 132 mg/mL). Despite the high concentrations needed to treat potentially resistant A. baumannii strains, it is notable that all 3 carbapenems showed a clinically attainable MIC 50 against A. baumannii (MIC 50 of doripenem, 0.5 mg/mL; MIC 50 of imipenem, 0.25 mg/mL; MIC 50 of meropenem, 0.5 mg/mL).
Another large-scale surveillance study undertaken by Pillar et al. [4] has provided additional information about the activity of doripenem against gram-negative pathogens. In that study, the activity of doripenem and various other antimicrobial agents was evaluated for 11,299 Enterobacteriaceae and P. aeruginosa isolates obtained from hospitals across the United States from 2005 through 2007. An analysis of the data showed that doripenem inhibited P. aeruginosa isolates at lower concentrations than did imipenem or meropenem (MIC 90 of doripenem, 4 mg/mL; MIC 90 of imipenem, 16 mg/mL; MIC 90 of meropenem, 8 mg/mL) (figure 1). The difference in inhibitory concentrations was not limited to P. aeruginosa isolates from a particular anatomical site. Four site-specific subanalyses (respiratory tract, blood, skin and wound, and urine) demonstrated that the MIC 90 of doripenem was lower than those of imipenem and meropenem for P. aeruginosa, regardless of the specimen source (table 2) .
In the TRUST-11 study, doripenem was as potent as meropenem and 110 times as potent as imipenem against Enterobacteriaceae species overall (MIC 90 of doripenem, 0.12 mg/mL; MIC 90 of imipenem, 2.0 mg/mL; MIC 90 of meropenem, 0.12 mg/ mL). The relative activity of doripenem, imipenem, and meropenem was similar against Enterobacteriaceae isolates from various anatomical sites (table 2) .
Susceptibility of isolates with resistance to the antimicrobial classes. In vitro studies have detailed the potency of the antimicrobial effects of doripenem against gram-negative pathogens that are overtly nonsusceptible to certain antimicrobial agents or that exhibit phenotypes consistent with the expression of specific resistance determinants. A recent Eurofins surveillance study evaluated the susceptibility of 19,624 pathogenic isolates (obtained from a combined total of 75 hospital laboratories throughout the United States and Europe from 2005 through 2006) to a wide variety of antimicrobial agents (Eurofins Medinet, unpublished data). The potency of doripenem among US isolates of E. coli and K. pneumoniae was reduced by only a factor of 2 when a ceftazidime-nonsusceptible phenotype, as opposed to a ceftazidime-susceptible phenotype, was present (MIC 90 for E. coli, 0.06 mg/mL for ceftazidime-nonsusceptible vs. 0.03 mg/mL for ceftazidime-susceptible isolates; MIC 90 for K. pneumoniae, 0.12 mg/mL vs. 0.06 mg/mL). Among E. coli and K. pneumoniae isolates, doripenem's in vitro potency against isolates with phenotypes consistent with extended-spectrum b-lactamase (ESBL) expression was 2-fold lower than that against isolates that had ESBL-negative phenotypes (MIC 90 for E. coli, 0.06 mg/mL for ESBL-positive phenotype vs. 0.03 mg/ mL for ESBL-negative phenotype; MIC 90 for K. pneumoniae, 0.12 mg/mL vs. 0.06 mg/mL). It was notable that doripenem's potency against ceftazidime-nonsusceptible Enterobacter cloacae isolates obtained from US laboratories (MIC 90 , 0.25 mg/mL) was 4-fold lower than that against ceftazidime-susceptible E. cloacae isolates (MIC 90 , 0.06 mg/mL). The MIC 90 of doripenem with respect to ceftazidime-nonsusceptible E. cloacae was lower than the corresponding MIC 90 of meropenem (0.5 mg/mL) by NOTE. Assessment was done in a study that examined the potential for selection of single-step, drug-resistant mutants among 8 different P. aeruginosa strains, 7 of which were carbapenem-susceptible and 1 of which had a phenotype consistent with loss of the porin OprD. (Of the strains under study, all exhibited normal susceptibility to penicillins, with the exception of 1 carbapenem-susceptible strain that was supersusceptible to penicillins [carbenicillin MIC, р16 mg/mL]). MIC, minimum inhibitory concentration of the selective agent with respect to the P. aeruginosa strain being tested. Data are from Mushtaq et al. [7] . a factor of 2 and was lower than that of imipenem (2 mg/mL) by a factor of 8. Doripenem demonstrated a similar pattern of susceptibility against ceftazidime-nonsusceptible P. aeruginosa isolates. The MIC 90 of doripenem was 8-fold higher against these isolates than against ceftazidime-susceptible isolates (16 mg/mL for ceftazidime-nonsusceptible vs. 2 mg/mL for ceftazidime-susceptible isolates). Regardless, the MIC 90 of doripenem against ceftazidime-nonsusceptible isolates remained lower than that of imipenem (32 mg/mL) and meropenem (132 mg/mL).
POTENTIAL FOR SELECTION OF DRUG-RESISTANT MUTANTS
Doripenem has a relatively weak propensity to select for carbapenem-resistant mutants within bacterial populations. In a series of single-step mutation-selection experiments involving P. aeruginosa, Mushtaq et al. [7] found that 3 of the 8 tested P. aeruginosa strains yielded doripenem-resistant mutants after exposure to doripenem at concentrations у2 times the MIC. In contrast, 6-7 of those same 8 strains yielded drug-resistant mutants after exposure to each of the 2 other antipseudomonal carbapenems (imipenem and meropenem) at concentrations у2 times the MIC. Moreover, none of the 8 tested P. aeruginosa strains yielded doripenem-resistant mutants after exposure to doripenem at concentrations 14 times the MIC, in contrast to the other carbapenems evaluated (table 3) [7] . A series of serial passage experiments further confirmed that it was more difficult to select for resistance to doripenem than resistance to other carbapenem and noncarbapenem agents and that the magnitude of the increases in the MICs for doripenem was smaller for the resistant mutants [7] . Similar results regarding the limited ability of doripenem to select for resistant mutants were obtained by Sakyo et al. [6] , who found that, when each of 10 different P. aeruginosa strains was exposed to doripenem at a concentration that inhibited growth of the parent strain, selection for doripenem-resistant P. aeruginosa mutants occurred at a frequency ! mutants per cell per generation. By 8 ϫ 10 thermore, Sakyo et al. [6] observed that meropenem and imipenem typically selected for resistant mutants at higher multiples of their MIC than did doripenem and that the range of meropenem concentrations at which selection of resistant mutants occurred was generally wider than the range of doripenem concentrations at which selection of resistant mutants occurred. Santoro et al. [8] exposed 32 P. aeruginosa clinical isolates to doripenem, meropenem, or imipenem at various multiples of the MIC and noted that, at 2 times the MIC, the numbers of carbapenem-resistant colonies selected with doripenem, compared with those selected with imipenem and meropenem, were similar. In contrast, at 4 times and 8 times the MIC, doripenem exposure yielded 35%-50% fewer strains with resistant colonies. Twenty of the mutants with selective increases in meropenem and imipenem MICs were evaluated and were found to be deficient in the OprD protein. Sequencing of the membrane protein OprD revealed 15 mutants with frameshift or stop mutations and 1 mutant with a Phe 1232 Ser substitution.
In a separate set of experiments in which clinical isolates of P. aeruginosa were exposed to doripenem and meropenem, Yamashiro et al. [10] found that the emergence of OprD-deficient P. aeruginosa mutants could be suppressed under some conditions. With use of both the disk-diffusion method and an in vitro pharmacodynamic model, strains of P. aeruginosa with reduced susceptibility to doripenem or meropenem were obtained and were identified as OprD deficient. The MIC of doripenem against the OprD-deficient mutants was 4-fold higher (MIC for mutants, 4 mg/mL) than that against susceptible P. aeruginosa clinical isolates (MIC, 1 mg/mL), whereas the MIC of meropenem for mutants was 4-8-fold higher (MIC for mutants, 8-16 mg/mL) than that against susceptible P. aeruginosa clinical isolates (MIC, 2 mg/mL). In the pharmacokinetic-pharmacodynamic analysis using autosimulation to produce various time-concentration curves of doripenem or meropenem on the basis of the human pharmacokinetic profiles in a phase 1 study, Yamashiro and colleagues observed that the regrowth of drugresistant mutants with a deficiency of OprD was prevented when the concentration of the antibiotic remained above the MIC for the mutants for у29% of the dosing interval. These findings suggest that a dosing regimen that produces a drug concentration that exceeds the MIC for mutants for 129% of the dosing interval would be sufficient to inhibit the emergence of drug-resistant mutants in P. aeruginosa clinical isolates.
Although resistance to doripenem is more difficult to develop and the magnitude of increases in MICs for doripenem is lower than those for meropenem and imipenem, it appears that, when resistance does arise, it is caused by mechanisms that are known to lead to carbapenem resistance. In the study by Mushtaq et al. [7] , single-step mutants were mostly resistant to carbapenems only and had reduced amounts of OprD, whereas multistep mutants demonstrated resistance to other classes, which implied other mechanisms, such as up-regulated efflux. The study by Sakyo et al. [6] also noted that carbapenems predominantly selected carbapenem-resistant mutants with reduced OprD. Santoro et al. [8] provided a more in-depth study of the mechanisms contributing to carbapenem resistance, including up-regulated efflux, OprD loss, and increases in AmpC production. The investigators noted that, among the mutants that demonstrated a greater relative increase in the meropenem or imipenem MIC, compared with the doripenem MIC, decreased OprD appeared to be the predominant mechanism of carbapenem resistance; consistent increases in efflux transcripts or in AmpC activity were not observed. Each of these studies demonstrated that OprD loss is the most common mechanism for in vitro development of drug resistance in P. aeruginosa and, in addition, that changes in efflux may play a role.
CONCLUSION
Doripenem is a broad-spectrum antimicrobial agent that combines the intrinsic activity of imipenem against gram-positive organisms with the intrinsic activity of meropenem against gram-negative organisms. The activity of doripenem against gram-negative organisms warrants particular attention, because in vitro testing has shown that this agent is a potent inhibitor of gram-negative pathogens that exhibit an elevated capacity for drug resistance, including P. aeruginosa and Enterobacteriaceae. This potent inhibitory activity appears to be retained largely when doripenem is directed against gram-negative pathogens that express certain problematic determinants of antimicrobial resistance, as well as when doripenem is directed against any of a number of gram-negative pathogens that may show some overt nonsusceptibility to other antimicrobials, such as ceftazidime-nonsusceptible E. coli and K. pneumoniae. Even for organisms such as ceftazidime-nonsusceptible E. cloacae and P. aeruginosa, in which susceptibility to doripenem is more substantially decreased (relative to what is seen in corresponding ceftazidime-susceptible strains), doripenem appears to demonstrate more potent activity than does either imipenem or meropenem. Also noteworthy are in vitro data indicating that doripenem has inhibitory effects at low concentrations against ∼30% of P. aeruginosa isolates that are not susceptible to imipenem. Moreover, doripenem, when compared with other carbapenems, shows a relatively weak ability to promote the emergence of antimicrobial resistance in vitro. Consequently, doripenem likely represents a valuable option for the treatment of infection in cases in which carbapenem therapy is warranted, particularly in cases in which a drug-resistant gram-negative organism is suspected to be the cause of infection.
